Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

Published:2019-10 Issue:10 Volume:7 Page:767-775
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Tsai Joy N,Lee Hang,David Natalie L,Eastell Richard,Leder Benjamin Z

Funder

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference40 articles.

1. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group;Black;Lancet,1996

2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group;Harris;JAMA,1999

3. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators;Ettinger;JAMA,1999

4. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis;Neer;N Engl J Med,2001

5. Denosumab for prevention of fractures in postmenopausal women with osteoporosis;Cummings;N Engl J Med,2009

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of romosozumab combined with routine therapy on pain relief, disease progression and adverse reactions in patients with postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Medicine;2024-08-14

2. Osteoporosis treatment: current drugs and future developments;Frontiers in Pharmacology;2024-08-12

3. What’s New in Osteoporosis: Emphasis on the Aging Athlete;Journal of Bone and Joint Surgery;2024-07-25

4. Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity;Frontiers in Pharmacology;2024-04-02

5. Exploration of Key Regulatory Factors for Continuous Regulation of Osteogenic Differentiation in Mesenchymal Stem Cells Based on Transcriptomic Sequencing;2024-02-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3